Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 8/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833929 | 0.91 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1TP53RAB9AKDM1A | |
| SCHEMBL4844726 | 0.88 | ABCC9 (0.38) | SMN1; SMN2NPC1TP53RAB9AKDM1A | |
| SCHEMBL4844276 | 0.86 | MDM2 (0.39) | SMN1; SMN2TP53RAB9AMAPTP4HB | |
| SCHEMBL4846988 | 0.85 | MAPT (0.38) | SMN1; SMN2RAB9AABCC9MAPTP4HB | |
| SCHEMBL4842742 | 0.85 | RAB9A (0.38) | SMN1; SMN2NPC1TP53RAB9AMAPT | |
| SCHEMBL4843102 | 0.82 | RAB9A (0.37) | SMN1; SMN2RAB9AABCC9MAPTCCNB2 | |
| SCHEMBL4841781 | 0.82 | ABCC9 (0.40) | SMN1; SMN2NPC1RAB9AABCC9MAPT | |
| SCHEMBL4835102 | 0.80 | MDM2 (0.39) | SMN1; SMN2TP53RAB9AABCC9MAPT | |
| SCHEMBL4844376 | 0.78 | KMT2A (0.45) | SMN1; SMN2NPC1TP53RAB9AKDM1A | |
| SCHEMBL4844365 | 0.78 | KMT2A (0.45) | SMN1; SMN2NPC1TP53RAB9AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | claimed |
| US-6956033-B2 | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | claimed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | claimed |
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1306373-B1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-6956033-B2 | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, TRPV1 | SMN1; SMN2 4086/4885NPC1 1943/4885TP53 357/4885 |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | SMN1; SMN2 144/4885NPC1 985/4885TP53 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.